19 Herein we describe the effects of semaglutide on the primary, confirmatory secondary, and select exploratory endpoints in a prespecified analysis, which was finalized in the statistical analysis plan before database lock, of patients with LVEF of 45% to 49%, 50% to 59%, and 60%
Reported or plausible effects may include headache, nausea, dizziness, flushing, fatigue, or changes in sleep
HPLC analysis and purification of peptides
To protect your patients health and your own liability, providers should have a clear, documented process they follow every time when deciding if a patient is a candidate for semaglutide drugs